FACT SHEET Company Overview Our Vision: To be the Global Leader in Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and Testing for Life cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, Our Mission: To contribute to a safer and forensics, advanced material sciences and in the support of clinical studies, as well as having an healthier world by providing our customers emerging global presence as a Contract Development and Manufacturing Organisation. The Group with innovative and high quality laboratory, also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing research and advisory services, whilst and in-vitro diagnostic products. creating opportunities for our employees and generating sustainable shareholder value History Eurofins Scientific was founded in 1987 with four employees to market the SNIF-NMR technology, Our Values: Customer Focus, Quality, a patented analytical method used to verify the origin and purity of several types of food and Competence & Team Spirit and Integrity beverages and identify sophisticated fraud not detectable by other methods. Today, the Eurofins Group is a leading provider of testing and analytical services with: • an international network of more than 800 laboratories in over 50 countries Revenues in EUR million • over 50,000 staff • a portfolio of over 200,000 analytical methods • more than 450 million tests performed each year Eurofins has been one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 34% each year (in compound average) to over EUR 5.4 billion in 2020. Furthermore, between the Initial Public Offering on 24 October 1997 (EUR 0.183) and 31 December 2020 (EUR 68.63), Eurofins’ share price has multiplied by 375x, an annual average increase of 29% (against 4% for the SBF 120, 3% for the CAC 40, 6% for the S&P 500 and 10% for the NASDAQ over the same period). Recent Developments In 2020, the Group has risen to the challenges of COVID-19, quickly developing a very broad range of products and services critical to the management of COVID-19. It set up, at pace, significant scale testing capacity and remained at the forefront of both scientific and product innovation. The Group supported the development of vaccines by most leading providers. It also innovated to produce new critical tests and testing formats for the individual and the workplace and recently the GSD Novatype® RT-PCR for fast variant identification. It launched new testing formats for the individual, such as the GSD NovaPrime® SARS-CoV-2, successfully validated for pharynx gargle and saliva Eurofins shares are listed on samples, as well as solutions for the workplace, such as the SAFER@WORK™ programmes, Euronext Paris designed to help companies set up advanced risk management protocols to limit the impact of (since IPO in October 1997) COVID-19, and Eurofins COVID-19 Sentinel™ waste water and environmental tests. The remaining business (excluding COVID-19 clinical testing and reagents revenues) demonstrated ISIN FR0014000MR3, Euronext ERF, Reuters EUFI.PA, Bloomberg ERF FP its strong resilience and delivered strong FY 2020 results, with positive year-on-year organic growth and 5% organic growth in Q4. Laboratories of the Group continued to make scientific advances and Euronext Paris: EURONEXT 100, SBF 120, SBF TOP innovations in multiple core business areas including the world’s first official method for the 80 EW, CAC ALL SHARES, CAC ALL-TRADABLE, CAC HEALTH CARE, CAC L60 RI SW, CAC LARGE identification of fructans certified by the AOAC and ISO bodies, the world’s first AOAC Performance SM 60, CAC LARGE 60 EW, CAC NEXT 20, EN H C Tested Methods status for a screening method to detect aflatoxin M1 in milk commodities, Viracor EQ&SER EW. TRAC™, a proprietary donor-derived cell-free DNA assay for detection of acute kidney rejection and TruGraf Liver, a unique, non-invasive blood-based test to support liver transplant patients. Euronext Amsterdam: EN CORE E100 EW, EN EUR N100 EW, EN EUROZONE 150 EW, EN EUROPE The Group continues to execute on its strategy and entered the final stage of its significant 2015- 500, EN EUROZONE 300, EN EZ L&M 60 EW. 2020 investment programme to create a global network of large state-of-the-art laboratories. 2 Other: MSCI Europe, STOXX Europe 600. Another 35,000 m of new or renovated laboratory and office space was added in 2020 and an additional 85,000 m2 are planned for 2021 and 2022, to bring the total surface of our facilities to over 1.5 million m2. Thanks to a fast-paced response to COVID-19 and the resilience of its core businesses, Eurofins Contact and Addresses delivered very strong FY 2020 results in terms of revenues (up by 19.2%), adjusted EBITDA margin Investor Relations (up to 26.0%) and cash flow (FCFF up by 143.5%) in 2020, ahead of its most recent objectives. [email protected] Tel +32 2 766 1620 Outlook Avenue Herrmann Debroux 48 The COVID-19 pandemic evolution and its impact over the coming months and years remains very B-1160 Brussels, Belgium much uncertain, especially considering the unknown efficacy of vaccines on new Variants of Concern. However, the speed of reaction and innovation shown by our entrepreneurial units to Please refer to our on-line group directory for laboratory contact information develop an unparalleled range of solutions to fight COVID-19 will no doubt enable our Group to capture significant opportunities in other areas in the future. .